Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy …
(NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has approved Dupixent® (dupilumab) as an add-on maintenance treatment for …Read More
